APPLICATIONS PUBLISHED 31 MARCH 2004
Published: 1-Sep-2004
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Method for treating glaucoma VI
Alteon 1401351*
Acorbyl-2-hexadecanoate as a NO-synthase inhibitor
L'Oreal 1401392*
NO-synthase inhibitor and use thereof
L'Oreal 1401393*
Osmotic implant with membrane and membrane retention means
Alza Corp 1401395*
Pharmaceutical and diagnostic compsns containing nanoparticles useful for treating targeted tissues and cells
Cornerstone Pharmaceuticals 1401396*
Pharmaceutical formulation having a masked taste and method for the production thereof
Aventis Pharma 1401397*
Pharmaceutical formulation for the efficient administration of apomorphine, 6AR-(-)-N-propyl-NO-rapomorphine and their derivatives and prodrugs thereof
Axon Biochemicals 1401398*
Pharmaceutical compsns containing polymer and drug assemblies
Pfizer Products 1401399*
Porous matrix comprising cross-linked particles
The University of Nottingham 1401400*
Method for high throughput screening using a small-scale mill or microfluidics
Lindner, Marie 1401401*
Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
TAP Pharmaceutical Products 1401402*
Medicinal compsns comprising a melting core encapsulated in a hydroxypropylmethylcellulose film
The Boots Company 1401403*
Method of encapsulating an active substance
Moolman, Francis 1401404*
Oral pharmaceutical compsns with improved bioavailability
Farmatron 1401405*
Delivery of a bioactive material
Elan Corp 1401406*
Porous sponge-like cellulosic material for treatment of injuries
Cellomeda 1401407*
Controlled heat induced rapid delivery of pharmaceuticals from a skin depot
Zars 1401408*
Stable powder inhalation dosage formulation
Boehringer Ingelheim Pharmaceuticals 1401409*
Immunomodulation and effect of cell processes relating to serotonin family receptors
Philadelphia Health and Education Corp 1401410*
Use of tyrosine kinase inhibitors for treating bone loss
AB Science 1401411*
Use of potent, selective and non-toxic C-kit inhibitors for treating tumour angiogenesis
AB Science 1401412*
Use of tyrosine kinase inhibitors for treating allergic diseases
AB Science 1401413*
Use of tyrosine kinase inhibitors for treating multiple sclerosis (MS)
AB Science 1401414*
Use of tyrosine kinase inhibitors for treating inflammatory diseases
AB Science 1401415*
Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
AB Science 1401416*
Compsns for the treatment of pigmentation disorders and methods for their manufacture
Medicis Pharmaceutical 1401417*
Topical treatments using alkanolamines
Perricone, Nicholas 1401418*
Benzenesulphonyl(thio)ureas for the treatment of septic shock and SIRS
Aventis Pharma Deutschland 1401419*
Perturbed membrane-binding compounds
NST Neurosurvival Technologies 1401420*
Method for the treatment of nail fungus and other microbial and mycotic conditions and compsns useful therefor
Bogart, Mark 1401421*
Halogenated compsn, method for preparing same and uses thereof
Mainnemare, Arnaud 1401422*
Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
Depomed Development 1401423*
Carbamate compsns for use in treating psychotic disorders
Ortho-McNeil Pharmaceutical 1401424*
Organometallic anti-tumour agent
Haemato-Basics 1401425*
PTPase inhibitors and method of using the same
The Cleveland Clinic Foundation 1401426*
Non-peptide GRH agents, pharmaceutical compsns and methods for their uses, and processes for preparing them
Agouron Pharmaceuticals 1401427*
Use of ascorbic acid for producing topical preparations with angiogenetic effects
Beiersdorf 1401428*
Use of potent, selective and non-toxic C-kit inhibitors for treating mastocytosis
AB Science 1401429*
Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and MRI diagnosis
Miravant Pharmaceuticals 1401430*
Human growth hormone antagonists
Genentech 1401431*
Modulators of peroxisome proliferator activated receptors (PPAR)
Eli Lilly 1401434*
Topical administration of thiazolyl amides
Bayer HealthCare 1401435*
Thiazolyl amides and their use as antiviral drugs
Bayer HealthCare 1401436*
Immune response modifiers for the treatment of periodontal disease
3M Innovative Properties 1401437*
Use of cyclopamine in the treatment of basal cell carcinoma and other tumours
Tas, Sinan; Avci, Oktay 1401438*
Use of bicyclo compounds for treating Alzheimer's disease
Elan Pharmaceuticals 1401439*
Methods of use of fluoroquinolone compounds against bacteria
SmithKline Beecham 1401440*
Allosteric adenosine receptor modulators
King Pharmaceuticals 1401441*
S-omeprazole (esomaprazole) inclusion complex with cyclodextrins
Cipla 1401442*
Novel anti-infectives
SmithKline Beecham 1401443*
Antihistamines for the treatment of nasal congestion and nasal obstruction
Schering 1401444*
Crystalline anticholinergic, method for their production, and use thereof in the production of a drug
Boehringer Ingelheim Pharma 1401445*
Tetrahydroquinolin derivatives for the inhibition of diseases associated with aberrant physiological response to endogenous oestrogen
Eli Lilly 1401446*
Use of inhibitors of the protease of the human immunodeficiency virus (HIV) to block cell migration and/or invasion, tissue infiltration and oedema for the therapy of diseases associated therewith
Istituto Superiore di Santa 1401447*
Antibacterial treatment of osteoarthritis
Orthogenetics 1401448*
Tetracyclic compounds as PDE-5 inhibitors
Lilly Icos 1401449*
New use of a pyridazinone derivative
Orion Corp 1401450*
Quinazoline derivatives which promote the release of parathyroid hormone
Novartis 1401451*
Beta-hydroxamine derivatives useful in the treatment of Alzheimer's disease
Elan Pharmaceuticals 1401452*
Protease inhibitors
SmithKline Beecham 1401453*
Use of corrinoids in the treatment of skin diseases
Regeneratio Pharma 1401454*
Use of a phosphate adsorbent to combat vascular diseases
SeBo 1401455*
